Roche’s Enspryng leads latest CHMP recommendations
CHMP adopted positive opinions for eight new medicines in its April meeting
Read More
Tag: Enspryng
Roche’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder
Enspryng is the first approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
